Stock ledger
$ARTV Insider Trading
Artiva Biotherapeutics, Inc.
5
Alerts Sent
100%
Hit Rate Here
5
Insider Buys 30d
0
Insider Sells 30d
This page is InsiderWatch’s own record for ARTV: every alert we sent on this stock, scored against real market prices, plus recent insider buying and selling reported to the SEC on Form 4.
Price and Our Alerts
$ARTV price
Daily closing prices
3M change
+4.4%
1Y high
$13.39
1Y low
$2.28
Our alerts
5
in this window
Prices from public market data and may be delayed. Markers show the days our alerts on this stock fired. Not investment advice.
Our Alerts on $ARTV
4 alerts on ARTV sent and pending: awaiting the next market close before the result appears here.
| Sent (ET) | Call | Alert | Result |
|---|---|---|---|
| Jul 20, 6:09 PM | BULLISH | RA Capital buys $1.4M more of Artiva Biotherapeutics | +21.4% ✓ hit |
Every alert we sent on ARTV is listed once scored, hits and misses alike. Result is the stock’s move from the alert to the graded exit of its catalyst window.
Recent Insider Activity
Open-market buys and sells in ARTV by the company’s own officers, directors, and large holders, as reported to the SEC on Form 4 in roughly the last 30 days.
Daily buy vs sell dollars
Open-market insider filings that passed the significance gates, last 30 days
Bought
$5.1M
30 days
Sold
$0
30 days
Net flow
+$5.1M
buying leads
Active days
5
with gated filings
| Filed (ET) | Insider | Action | Value |
|---|---|---|---|
| Jul 31 | RA CAPITAL MANAGEMENT, L.P.Director | BUY | $456k |
| Jul 31 | RA Capital Healthcare Fund LPDirector | BUY | $456k |
| Jul 31 | RA Capital Nexus Fund, L.P.Director | BUY | $456k |
| Jul 31 | RA Capital Nexus Fund III, L.P.Director | BUY | $456k |
| Jul 31 | Kolchinsky PeterDirector | BUY | $456k |
| Jul 31 | Shah Rajeev M.Director | BUY | $456k |
| Jul 28 | RA CAPITAL MANAGEMENT, L.P.Director | BUY | $413k |
| Jul 28 | RA Capital Healthcare Fund LPDirector | BUY | $413k |
| Jul 28 | RA Capital Nexus Fund, L.P.Director | BUY | $413k |
| Jul 28 | RA Capital Nexus Fund III, L.P.Director | BUY | $413k |
| Jul 28 | Kolchinsky PeterDirector | BUY | $413k |
| Jul 28 | Shah Rajeev M.Director | BUY | $413k |
| Jul 23 | RA CAPITAL MANAGEMENT, L.P.Director | BUY | $2.6M |
| Jul 23 | RA Capital Healthcare Fund LPDirector | BUY | $2.6M |
| Jul 23 | RA Capital Nexus Fund, L.P.Director | BUY | $2.6M |
| Jul 23 | RA Capital Nexus Fund III, L.P.Director | BUY | $2.6M |
| Jul 23 | Kolchinsky PeterDirector | BUY | $2.6M |
| Jul 23 | Shah Rajeev M.Director | BUY | $2.6M |
| Jul 20 | RA CAPITAL MANAGEMENT, L.P.Director | BUY | $1.4M |
| Jul 20 | RA Capital Healthcare Fund LPDirector | BUY | $1.4M |
| Jul 20 | RA Capital Nexus Fund, L.P.Director | BUY | $1.4M |
| Jul 20 | RA Capital Nexus Fund III, L.P.Director | BUY | $1.4M |
| Jul 20 | Kolchinsky PeterDirector | BUY | $1.4M |
| Jul 20 | Shah Rajeev M.Director | BUY | $1.4M |
| Jul 14 | RA CAPITAL MANAGEMENT, L.P.Director | BUY | $194k |
| Jul 14 | RA Capital Healthcare Fund LPDirector | BUY | $194k |
| Jul 14 | RA Capital Nexus Fund, L.P.Director | BUY | $194k |
| Jul 14 | RA Capital Nexus Fund III, L.P.Director | BUY | $194k |
| Jul 14 | Kolchinsky PeterDirector | BUY | $194k |
| Jul 14 | Shah Rajeev M.Director | BUY | $194k |
Sourced from public SEC Form 4 filings. Buys shown are open-market purchases; routine grants and plan sales are filtered out before a trade reaches this log.
See the latest alerts across all stocks, the complete scored track record, this week’s insider buying, or the congress trading tracker.
Get the Next ARTV Alert When It Fires.
Everything here is already graded and public. Subscribers got it the minute it fired. Pro members get every alert; Watchlist members get the ones on stocks they follow. Free for 7 days, cancel any time.
Try Free for 7 DaysPast performance is not indicative of future results. Directional scoring measures a catalyst-matched window on daily closing prices and does not reflect fees, slippage, taxes, or execution. InsiderWatch is an informational service based on publicly available information only and is not financial, investment, legal, or tax advice. Outcomes are scored automatically against public market data by our own systems and are not independently audited.